Education
About Us
Working with TipRanks
Follow Us
Neuropace, Inc. (NPCE)
:NPCE
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -13.28%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth driven by the RNS System and improvements in gross margin, alongside successful equity financing and positive clinical results. However, there were challenges with increased R&D expenses and the decision to terminate SEEG product distribution. Overall, the highlights significantly outweigh the lowlights, indicating a positive outlook.Company Guidance
During NeuroPace's first quarter 2025 earnings call, the company provided optimistic guidance, projecting total revenue for the year to range between $93 million and $97 million, marking an increase of approximately 16% to 21% over 2024. This growth is expected to be primarily driven by a 26% year-over-year increase in RNS System sales, excluding NAUTILUS study implants from 2024, and a continued contribution from SEEG product sales. NeuroPace also anticipates a gross margin between 73% and 75% for 2025, supported by improved manufacturing efficiency that resulted in a 77% gross margin in Q1. Operating expenses are projected to be between $92 million and $95 million, with a focus on balancing revenue growth and cost management to achieve cash flow breakeven by the end of 2027. The company remains on track for a 20% plus CAGR through 2027, despite its decision to terminate SEEG product distribution by Q3 2025 due to shifting focus towards higher-margin RNS opportunities.Strong Revenue Growth
NeuroPace generated total revenue of $22.5 million in Q1 2025, an increase of 24% compared to $18.1 million in Q1 2024, primarily driven by strong growth in the core RNS business.
Record RNS System Sales
RNS sales increased by 26%, or 29% when excluding the impact of NAUTILUS study implants in Q1 2024, driven by sustained strength in RNS adoption at Level 4 centers and Project CARE activities.
Improved Gross Margin
Gross margin for Q1 2025 was 77%, up from 73.6% in Q1 2024, benefiting from improved manufacturing efficiency and higher RNS sales volume.
Successful Equity Financing
Completed a $75 million follow-on equity financing, adding high-quality shareholders and strengthening the balance sheet.
Positive Clinical Results
Presented three-year effectiveness data from the Post-Approval study of the RNS System showing an 82% median reduction in seizures and 42% of participants experiencing more than six months of seizure freedom.
NPCE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NPCE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $12.95 | $15.60 | +20.46% |
Mar 04, 2025 | $11.92 | $11.63 | -2.43% |
Nov 12, 2024 | $7.14 | $9.15 | +28.15% |
Aug 13, 2024 | $7.28 | $6.77 | -7.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neuropace, Inc. (NPCE) report earnings?
Neuropace, Inc. (NPCE) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Neuropace, Inc. (NPCE) earnings time?
Neuropace, Inc. (NPCE) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NPCE EPS forecast?
NPCE EPS forecast for the fiscal quarter 2025 (Q2) is -0.22.